Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia – results from a phase II pivotal clinical trial

Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home messages of his award presentation, which focused on Philadelphia-positive acute lymphoblastic leukaemia research. The presentation […]

The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL. The […]

The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO […]